10% Free customization
This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
“High Demand for Combination Therapy and Pressure Point Therapy Likely to Boost CINV & PONV Market”
FEATURED COMPANIES
- Eisai Co., Ltd.
- Helsinn Holding S.A.
- Merck & Co., Inc.
10% Free customization
This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
Chemotherapy-Induced Nausea and Vomiting (CINV) is one of the devastating side effects for patients undergoing cancer treatment. It is caused when various types of poisonous substances such as chemotherapeutic agents enter in the human body and alert the digestive system during chemotherapy. Besides chemotherapy, there are various types of factors that puts a patient high risk for CINV including female sex, history of alcohol use, CINV & motion sickness and anxiety or depression.
Postoperative Nausea and Vomiting (PONV) is referred to as a situation in which an inpatient experiences nausea and/or vomiting within the first 24-48 hours after undergoing surgery with general anesthesia. The incidence of PONV is 30% in the all post-surgical patients and 80% in high-risk patients. PONV is caused due to various factors including anesthetic choices, patient and surgery-specific. Treatment of PONV is done through prophylaxis and rescue treatment.
The U.S. emerged as a major region for the CINV & PONV market due to rising healthcare concerns and expenditure of the U.S. populace and growing CINV & PONV patient population.
The global CINV & PONV market is expected to grow with increasing cancer incidence, growing female population, increasing pharmaceutical R&D spending, growing healthcare expenditure and accelerating economic growth. Key trends and developments of this market includes progressing drugs under pipeline, high demand for combination therapy and increasing preference for pressure point therapy. However, there are some factors which can hinder growth of the market including entry of generics, stringent regulations and treatment cost.
The report “Global Chemotherapy-Induced Nausea and Vomiting (CINV) & Postoperative Nausea and Vomiting (PONV) Market: Industry Analysis & Outlook (2018-2022)” provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers, key tends & developments and challenges of the market, covering the U.S., Europe along with the global market. The report profiles the key players of the market including Merck & Co., Inc., Kirin Holding Company Limited (ProStrakan), Eisai Co., Ltd. and Helsinn Holding S.A.Please note: 10% free customization equates to up to 3 hours of analyst time.
Postoperative Nausea and Vomiting (PONV) is referred to as a situation in which an inpatient experiences nausea and/or vomiting within the first 24-48 hours after undergoing surgery with general anesthesia. The incidence of PONV is 30% in the all post-surgical patients and 80% in high-risk patients. PONV is caused due to various factors including anesthetic choices, patient and surgery-specific. Treatment of PONV is done through prophylaxis and rescue treatment.
The U.S. emerged as a major region for the CINV & PONV market due to rising healthcare concerns and expenditure of the U.S. populace and growing CINV & PONV patient population.
The global CINV & PONV market is expected to grow with increasing cancer incidence, growing female population, increasing pharmaceutical R&D spending, growing healthcare expenditure and accelerating economic growth. Key trends and developments of this market includes progressing drugs under pipeline, high demand for combination therapy and increasing preference for pressure point therapy. However, there are some factors which can hinder growth of the market including entry of generics, stringent regulations and treatment cost.
The report “Global Chemotherapy-Induced Nausea and Vomiting (CINV) & Postoperative Nausea and Vomiting (PONV) Market: Industry Analysis & Outlook (2018-2022)” provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers, key tends & developments and challenges of the market, covering the U.S., Europe along with the global market. The report profiles the key players of the market including Merck & Co., Inc., Kirin Holding Company Limited (ProStrakan), Eisai Co., Ltd. and Helsinn Holding S.A.Please note: 10% free customization equates to up to 3 hours of analyst time.
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Eisai Co., Ltd.
- Helsinn Holding S.A.
- Merck & Co., Inc.
1. CINV & PONV Overview
2. Global CINV & PONV Market
3. Regional CINV & PONV Market
4. Market Dynamics
5. Competitive Landscape
6. Company Profiles
List of Figures
List of Tables
Note: Product cover images may vary from those shown
LOADING...
- Merck & Co., Inc.
- Eisai Co., Ltd.
- Kirin Holding Company, Limited (ProStrakan)
- Helsinn Holding S.A.
Note: Product cover images may vary from those shown